• Kalaris reported positive expanded Phase 1a single-ascending-dose data for TH103 in neovascular AMD, supporting potential longer treatment durability.
• Expanded dataset included 17 treatment-naive patients; 41% needed first retreatment at 4 months or later, 29% needed none through 6 months.
• Plasma pharmacokinetics showed 27- to 53-fold lower Cmax versus leading anti-VEGF agents on a molar-equivalent basis, implying higher intraocular retention.
• Phase 1b/2 multiple-ascending-dose trial remains enrolling; initial data expected in 1H 2027 to guide Phase 3 dose selection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607170700PRIMZONEFULLFEED9763838) on July 17, 2026, and is solely responsible for the information contained therein.